Insider Buying: Aquestive Therapeutics (NASDAQ:AQST) Director Acquires $99,208.50 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Director Richard Daly purchased 28,025 shares of Aquestive Therapeutics stock in a transaction on Tuesday, November 10th. The stock was bought at an average cost of $3.54 per share, for a total transaction of $99,208.50. Following the transaction, the director directly owned 28,025 shares in the company, valued at $99,208.50. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Aquestive Therapeutics Stock Performance

Shares of AQST traded up $0.34 during midday trading on Friday, hitting $3.91. The company had a trading volume of 3,962,404 shares, compared to its average volume of 2,592,764. The company’s 50-day simple moving average is $4.37 and its 200-day simple moving average is $4.22. The firm has a market capitalization of $491.45 million, a P/E ratio of -6.11 and a beta of 1.49. Aquestive Therapeutics, Inc. has a 1 year low of $2.93 and a 1 year high of $6.74.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $7.56 million during the quarter, compared to analyst estimates of $11.02 million. Equities analysts predict that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AQST. Blue Owl Capital Holdings LP acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth $3,923,000. Latash Investments LLC purchased a new stake in Aquestive Therapeutics in the second quarter valued at $1,011,000. Wasatch Advisors LP lifted its position in Aquestive Therapeutics by 57.8% in the second quarter. Wasatch Advisors LP now owns 1,385,843 shares of the company’s stock valued at $5,765,000 after acquiring an additional 507,527 shares during the last quarter. BlackRock Inc. purchased a new stake in Aquestive Therapeutics in the second quarter valued at $33,569,000. Finally, Walleye Capital LLC acquired a new position in Aquestive Therapeutics in the second quarter valued at $1,175,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AQST has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price target on shares of Aquestive Therapeutics in a report on Thursday, September 10th. Wall Street Zen downgraded shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, October 16th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.75.

About Aquestive Therapeutics

Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company’s products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.